116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

BACKGROUND: Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) injectable suspensions have demonstrated efficacy in phase III studies. POLAR assessed antiviral activity and safety of CAB LA+RPV LA, administered every 2 mos (Q2M), in HIV-1 infected, antiretroviral therapy–experienced adults wh...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Mills, Anthony, Richmond, Gary J, Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Andany, Nisha, Margolis, David, Sutton, Kenneth, Wilches, Viviana, Roberts, Jeremy, McCoig, Cynthia C, Vandermeulen, Kati, Spreen, William
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Poster Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778199/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.426
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars